Ibex secures PathLAKE contracts to roll out AI-based cancer diagnostics to UK hospitals - The EE

Ibex secures PathLAKE contracts to roll out AI-based cancer diagnostics to UK hospitals

Ibex Medical Analytics (Ibex), an AI-powered cancer diagnostics, has announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer diagnosis at 25 NHS Trusts.

PathLAKE is a UK centre of excellence consortium, founded by Innovate UK, that is delivering AI innovation in pathology across NHS Trusts and UK universities including Nottingham University Hospitals, University Hospitals Coventry & Warwickshire, and Oxford University Hospitals. The contract award follows a rigorous selection process which recognised Ibex as the top scoring solution provider for both the breast and prostate cancer categories, allowing up to 25 NHS Trusts to directly procure the Ibex Galen Breast and Galen Prostate solutions. Cambridge University Hospitals is one of the Trusts to subsequently select Ibex to support its pathologists by augmenting diagnostic workflows with enhanced quality, accuracy and efficiency.

“Cambridge University Hospitals is very proud to be a founding partner of PathLAKE Plus, teaming up to help secure the £13.5 million grant from the Industrial Strategy Challenge Fund,” says Rebecca Brais, clinical lead for digital pathology and major projects in diagnostics and consultant histopathologist at Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust. “We see ourselves, and the UK as a whole, at the of innovation in digital pathology and look forward to implementing the Ibex Galen solution here in Cambridge as part of our Histopathology Team’s digital transformation.”

The worldwide shortage of pathologists combined with a rise in the number of cancer cases and their complexity has led to growing workloads imposed on pathology departments and delays in cancer diagnosis across the UK. With approximately 275,000 women undergoing breast biopsies and 100,000 men undergoing prostate biopsies in the UK each year, there is a growing need for AI-powered solutions and decision-support tools that help pathologists detect cancer rapidly with the utmost accuracy.

The Galen suite of solutions from Ibex is widely deployed AI technology for pathology, used in routine clinical practice at laboratories, hospitals, and health systems worldwide. It supports pathologists in a variety of tasks during the diagnosis of breast, prostate, and gastric biopsies and helps improve the accuracy of cancer diagnosis, reduce turnaround time, boost productivity, and improve user experience. Galen demonstrated outstanding outcomes across multiple clinical studies performed on various tissue types and diagnostic workflows.

“We are extremely honored to be recognised by PathLAKE as a provider of AI solutions in pathology,” says Richard Nicholson, director of sales, UK at Ibex. “Our team looks forward to supporting additional regions of the UK with our suite of Galen solutions. Building upon our successful AI deployments in NHS Wales, and our existing projects with hospitals and labs in England, we are positioned to further strengthen the adoption, deployment and routine use of AI in pathology across the UK.”

Follow us and Comment on Twitter @TheEE_io

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.